AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Economists around the world are expecting muted U.S. economic growth in coming quarters, and some indicators suggest a mild recession is a possibility. It may become difficult for investors to ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

After a season of regulatory upheaval, obesity and rare genetic diseases will likely remain major themes for biopharma in ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.